Verition Fund Management
RPRX icon

Verition Fund Management’s Royalty Pharma RPRX Stock Holding History

Verition Fund Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21M Buy
+75,000
New +$3.9M 0.02% 729
2026
Q1 		– Sell
-95,068
Closed -$3.67M – 3344
2025
Q4 		$3.67M Sell
95,068
-206,000
-68% -$7.86M 0.01% 1105
2025
Q3 		$10.6M Buy
301,068
+167,492
+125% +$6.06M 0.04% 491
2025
Q2 		$4.81M Sell
133,576
-1,741
-1% -$57.7K 0.02% 1154
2025
Q1 		$4.21M Buy
135,317
+36,278
+37% +$1.15M 0.02% 979
2024
Q4 		$2.53M Buy
99,039
+71,170
+255% +$1.89M 0.01% 1402
2024
Q3 		$788K Buy
27,869
+7,919
+40% +$219K ﹤0.01% 2049
2024
Q2 		$526K Sell
19,950
-1,431
-7% -$39.7K ﹤0.01% 2028
2024
Q1 		$649K Sell
21,381
-8,533
-29% -$252K ﹤0.01% 1872
2023
Q4 		$840K Sell
29,914
-3,076
-9% -$84.5K 0.01% 1261
2023
Q3 		$895K Sell
32,990
-8,915
-21% -$265K 0.01% 1140
2023
Q2 		$1.29M Buy
41,905
+23,521
+128% +$797K 0.02% 842
2023
Q1 		$662K Sell
18,384
-13,798
-43% -$512K 0.01% 1102
2022
Q4 		$1.27M Sell
32,182
-1,946
-6% -$81.2K 0.02% 813
2022
Q3 		$1.37M Buy
34,128
+25,215
+283% +$1.08M 0.02% 1167
2022
Q2 		$375K Sell
8,913
-37,500
-81% -$1.54M 0.01% 1612
2022
Q1 		$1.81M Buy
+46,413
New +$1.82M 0.02% 1047
2021
Q4 		– Sell
-20,299
Closed -$734K – 2771
2021
Q3 		$734K Sell
20,299
-12,701
-38% -$494K 0.01% 1062
2021
Q2 		$1.35M Buy
33,000
+27,146
+464% +$1.15M 0.01% 679
2021
Q1 		$255K Buy
+5,854
New +$278K ﹤0.01% 1204

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's RPRX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 75,000 shares worth $4.21M. The stake represents 0.02% of the portfolio and ranks #729 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in RPRX as recently as Q4 2025.

Verition Fund Management first reported a position in RPRX in Q1 2021 and has held it in 20 quarters since. The position peaked at $10.6M in Q3 2025. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Verition Fund Management held 75,000 shares of Royalty Pharma worth $4.21M as of Q2 2026.
  • Royalty Pharma was a new Verition Fund Management position in Q2 2026.
  • Royalty Pharma made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #729 holding.
  • Verition Fund Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 20 quarters since.
  • Verition Fund Management's Royalty Pharma position peaked at $10.6M in Q3 2025.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.